TABLE 4.
Functional classes/pathways of immune response genes regulated postinfection with PRV Be and/or treatment with IFNβa
| Accession no. | Gene | Avg increase (n-fold)a
|
|||||
|---|---|---|---|---|---|---|---|
| IFN
|
IFN + PRV Be
|
PRV Be
|
|||||
| 3 h | 12 h | 3 h | 12 h | 3 h | 12 h | ||
| MHC class I antigen presentation | |||||||
| AI170268 | Beta-2-microglobulin | 3.0 | 5.2 | 3.7 | 6.9 | − | − |
| M31018 | MHC class I alpha chain precursor | 3.2 | 5.3 | 3.3 | − | − | − |
| M24324 | MHC class I CE1 | − | 4.9 | − | 3.6 | − | − |
| M24026 | MHC class I RT1 (RT44), u haplotype | − | 4.8 | − | − | − | − |
| M11071 | MHC class I RT1.A(n) heavy chain precursor | − | − | 3.0 | − | − | − |
| X67504 | MHC class I RT1.Au heavy chain precursor | 15.4 | − | 12.4 | − | − | − |
| M11071 | MHC class I RT1.Aw3 | − | 4.3 | − | − | − | − |
| L40362 | MHC class I RT1.C type | − | 3.3 | − | − | − | − |
| AF074609 | MHC class I RT1-EC2 | − | 3.8 | − | − | − | − |
| AF074609 | MHC class I RT1-EC3 | − | 4.1 | − | − | − | − |
| M10094 | MHC class I truncated cell surface antigen | 4.0 | 5.9 | 4.9 | − | − | − |
| AF025308 | MHC class Ia RT1-A2 | 3.6 | 6.6 | 3.3 | − | − | − |
| L23128 | MHC class Ib RT1, H2-TL-like | 18.3 | 16.0 | 16.4 | 6.9 | − | − |
| AI235890 | MHC class Ib RT1-BM1, alpha chain | 43.3 | 57.5 | 35.0 | 8.4 | − | − |
| L40364 | MHC class Ib RT1-CE12 | 5.5 | 7.2 | 5.6 | 3.8 | − | − |
| U16025 | MHC class Ib RT1-M3 | 11.1 | 19.2 | 3.9 | − | − | − |
| AF029240 | MHC class Ib RT1-S3 | 5.4 | 4.0 | 5.5 | 3.4 | − | − |
| D45249 | Proteasome activator rPA28 subunit alpha | − | 4.9 | − | − | − | − |
| D45250 | Proteasome activator rPA28 subunit beta | 3.1 | 9.8 | − | − | − | − |
| D10729 | Proteasome subunit beta type 8 precursor | 5.8 | 15.0 | 4.1 | − | − | − |
| D10757 | Proteasome subunit R-RING12 | 24.3 | 62.6 | 15.8 | 7.7 | − | − |
| X57523 | Tap1/antigen peptide transporter | 31.3 | 27.8 | 24.1 | 6.8 | − | − |
| X63854 | Tap2/antigen peptide transporter | 3.5 | − | 3.8 | − | − | − |
| Complement | |||||||
| AA891576 | Complement component 1, q subcomponent | − | − | − | 8.5 | − | 9.1 |
| AA799803 | Serine protease homologous to C1r precursor | − | 7.0 | − | − | − | − |
| D88250 | Serine protease homologous to C1s precursor | − | 14.8 | − | − | − | − |
| Cytokines/receptors/inflammatory response | |||||||
| Y07704 | Best5/viperin | 206.5 | 228.3 | 263.8 | 257.4 | 13.9 | 12.6 |
| AF030358 | Fractalkine precursor (C-X3-C) motif | − | − | 13.2 | 3.5 | 16.5 | 9.8 |
| U48592 | Interleukin-1 receptor accessory protein | − | − | 5.8 | 10.3 | − | − |
| U69272 | Interleukin-15 | 3.7 | − | − | − | − | − |
| AF087944 | Monocyte differentiation antigen CD14 precursor | − | − | − | 3.7 | − | 3.3 |
| U17035 | Small inducible cytokine B subfamily (CXC10) | 443.1 | 245.1 | 538.7 | 242.9 | 171.7 | 79.7 |
| L11035 | T-cell receptor alpha chain | − | − | − | 8.7 | − | 10.3 |
| IFN regulatory factors | |||||||
| M34253 | IFN regulatory factor 1 (IRF1) | 16.4 | 8.4 | 17.1 | 4.3 | 3.8 | − |
| AA799861 | IFN regulatory factor 7 (IRF7) | 126 | 229.4 | 109.6 | 520.1 | − | 17.7 |
| Antiviral effect | |||||||
| Z18877 | 2′-5′ oligoadenylate synthetase 1 | 3.3 | 9.9 | − | 3.9 | − | − |
| AF068268 | 2′-5′ oligoadenylate synthetase 2 | 37.8 | 42.4 | 22.0 | − | − | − |
| X52711 | Mx1 | 95.4 | 173.3 | 60.6 | 18.2 | − | − |
| X52713 | Mx3 | 135.2 | 267.7 | 109.5 | − | − | − |
| AI013987 | PKR | 37 | 18.9 | 37.2 | 13.2 | − | 3.5 |
a
The average increase compared to mock-treated cells is indicated for each experimental condition. −, not significantly different or absent.